EFFECT OF LIDOFLAZINE ON CORONARY FLOW RESERVE

我们以前已经证明， X综合征（尽管冠状动脉造影正常但胸痛） 动脉）由于有限的冠状动脉血流而具有心肌缺血 储备（微血管性心绞痛）。 因为利多夫嗪，一种钙 进入阻滞剂，改善胸痛症状和努力耐力 在微血管性心绞痛患者中，我们研究了 本品对10例冠心病患者进行了治疗， 微血管性心绞痛 所有患者在以下时间均出现明显症状： 传统的钙通道阻滞剂， 利多卡因240-360 mg/d治疗。 相比 冠状动脉（心大静脉）流量测量 利多卡因可改善冠状动脉血流 对起搏应激的反应，即使在给予麦角新碱后 0.15mg. 此外，药物治疗后的冠状动脉血流储备 潘生丁0.75mg/kg对血管的舒张作用也显著 提高 因此，利多夫嗪导致显著改善 压力和药理学冠状动脉血流储备，并表明， 微血管性心绞痛患者的冠脉血流储备 受与钙异常相关的血管收缩剂影响的限制 剂.

We have previously demonstrated that may patients with Syndrome X (chest pain despite angiographically normal coronary arteries) have myocardial ischemia due to limited coronary flow reserve (microvascular angina). Because lidoflazine, a calcium entry blocker, improves chest pain symptoms and effort tolerance in patients with microvascular angina, we studied the effect of this drug on coronary hemodyanmics in 10 patients with microvascular angina. All had been significantly symptomatic on conventional calcium channel blockers and had improved symptomatically on lidoflazine 240-360 mg/d. Compared to measurement of coronary (great cardiac vein) flow off all medications, lidoflazine resulted in improved coronary flow response to pacing stress, even after administration of ergonovine 0.15mg. Further, coronary flow reserve following pharmacologic vasodilation by dipyridamole 0.75 mg/kg was also significantly improved. Thus, lidoflazine results in significant improvement in stress and pharmacologic coronary flow reserve, and suggests that coronary flow reserve in patients with microvascular angina is limited by vasoconstrictor influences related to abnormal calcium fluxes.